Efficacy and Safety of Second‐Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study
ABSTRACT Background Immune checkpoint inhibitor (ICI) has reshaped the treatment landscape of esophageal squamous cell carcinoma (ESCC). But most patients end up with disease progression and/or therapeutic intolerance. The subsequent ICI rechallenge raises some discussions. Methods A retrospective s...
Saved in:
Main Authors: | Wensi Zhao, Nan Zhao, Dedong Cao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-07-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.70131 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy in advanced esophageal squamous cell cancer: earlier or later?
by: Shuang Wei, et al.
Published: (2025-07-01) -
Rechallenge following seizure in a patient receiving continuous theta burst stimulation for alcohol dependence
by: Venkata Lakshmi Narasimha, et al.
Published: (2025-09-01) -
Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study
by: Chen TF, et al.
Published: (2025-06-01) -
Dual Targeting of Inflammatory and Immune Checkpoint Pathways to Overcome Radiotherapy Resistance in Esophageal Squamous Cell Carcinoma
by: Qu Z, et al.
Published: (2025-07-01) -
Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma
by: Xiang Han, et al.
Published: (2025-12-01)